Clinical trials: Benign Hyperplasia of Prostate
Nocturia, Benign Prostatic Hyperplasia
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied…
- Trial name
- BPH (NCT02106182)
- Testing
- Silodosin, Laboratory tests, 3-days voiding diary
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter
A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.
- Trial name
- EVEREST-I (NCT03423979)
- Testing
- Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel
- Where
- 5 sites in Dominican Republic, Panama
- Volunteers
- 80 people
- Sponsor
- Urotronic Inc.
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
A dual-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent following treatment with the AQUABEAM System.
- Trial name
- AHAIII (NCT04308070)
- Testing
- AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent
- Where
- India
- Volunteers
- 26 people
- Sponsor
- PROCEPT BioRobotics
Treatment of Benign Prostatic Hyperplasia
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device.
- Trial name
- NCT02683980
- Testing
- Lumenis Pulse P120H and Xpeeda side firing fiber
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
BPH (Benign Prostatic Hyperplasia), BPH
INTUPRO in the Treatment of Benign Prostatic Hyperplasia-Related Symptoms
The goal of this clinical trial is to determine whether INTUPRO can improve the quality of life in patients with Benign Prostate Hyperplasia (BPH).
- Conditions
- BPH (Benign Prostatic Hyperplasia), BPH, BPH With Other Lower Urinary Tract Symptoms
- Trial name
- NCT07381127
- Testing
- INTUPRO ionic fluid
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- inTumo Therapeutics, Inc.
Prostate Hyperplasia
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of…
- Trial name
- NCT02244294
- Testing
- FLOMAX® capsules
- Volunteers
- 176 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS)
Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.
This is a prospective, randomized, open-label, parallel-group post-market clinical trial (PMCT). The overall objective of this PMCT is to compare the effectiveness, durability, and patient-centered outcomes of the Zenflow Spring…
- Conditions
- Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS), Enlarged Prostate
- Trial name
- NCT07797348
- Testing
- Zenflow Arm: Zenflow Spring System implant procedure, Medical Therapy Tamsulosin
- Volunteers
- 110 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia
The Zenflow Spring System EU Safety and Performance Study
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- ZEST EU (NCT03577236)
- Testing
- Zenflow Spring System
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 50 people
- Sponsor
- Zenflow, Inc.
Prostatic Hyperplasia
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
The primary objective of the study is to demonstrate the superiority of SL77.0499-10 10mg once daily over placebo and the non-inferiority versus tamsulosin hydrochloride after 12 weeks treatment in terms of the efficacy in…
- Trial name
- NCT00399464
- Testing
- alfuzosin
- Where
- Japan
- Volunteers
- 1,177 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia (BPH)
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation.
- Trial name
- PERMIN (NCT01604811)
- Testing
- Permixon® 160 mg, Tamsulosine Arrow LP
- Where
- 32 sites in France, Italy and 2 more
- Volunteers
- 206 people
- Sponsor
- Pierre Fabre Medicament
Prostatic Hyperplasia
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms…
- Trial name
- NCT00280605
- Testing
- Alfuzosin
- Volunteers
- 200 people
- Sponsor
- Sanofi
Calculi, Renal, Calculi, Urinary
Modified SOLTIVE Study
This is a study to collect procedural data during the use of the SOLTIVE™ Premium SuperPulsed Laser System in the treatment of bladder, ureteral, and kidney stones and BPH to inform the development of software algorithms.
- Conditions
- Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
- Trial name
- NCT07838077
- Testing
- SOLTIVE Premium SuperPulsed Laser System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Olympus Corporation of the Americas
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia (BPH)
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
- Trial name
- VAPEUR (NCT04838769)
- Testing
- REZŪM, alpha blocker and 5-alpha reductase inhibitor
- Where
- 21 sites in Australia, France
- Volunteers
- 155 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
- Trial name
- STRONG (NCT01259531)
- Testing
- Silodosin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
This is a prospective, pilot, open-label, uncontrolled, non-randomized safety and effectiveness study of OCL 503 in men with BPH.
- Trial name
- NCT02509975
- Testing
- Prostate artery embolization.
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- IMBiotechnologies Ltd.
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Benign Prostatic Hyperplasia (BPH)
A Comparative Study of KSO-0400 in BPH Patients With LUTS
The objective of this study is to evaluate the efficacy and safety of KSO-0400 compared to placebo for the treatment of LUTS caused by BPH.
- Trial name
- NCT01222650
- Testing
- KSO-0400, Silodosin
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Prostatic Hyperplasia
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with…
- Trial name
- NCT00090103
- Testing
- dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
- Where
- 503 sites in United States, Argentina and 34 more
- Volunteers
- 4,844 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia…
- Trial name
- NCT02244255
- Testing
- FLOMAX® capsules, Ascending doses of HYTRIN® capsules
- Volunteers
- 1,993 people
- Sponsor
- Boehringer Ingelheim